Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (January 2026)
25 slides from Maia Biotechnology's investor presentation, Jan 13, 2026
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA January 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are “forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; sta
Slide 3: Investment Profile
INVESTMENT PROFILE NYSE American: MAIA C) Newscience for cancer therapy with dual mechanism of action: Telomere Targeting and Immunogenicity e Ateganosine (THIO): lead molecule in 2 ongoing clinical trials (Phase 3 and Phase 2) ¢ Second generation compounds in R&D UO) Phase 3 Trial THIO-104: Ategano
Slide 4: Investment Profile
INVESTMENT PROFILE NYSE American: MAIA UC) Multiple Ateganosine (THIO) + checkpoint inhibitor trials planned for additional cancer indications ° BeOne Medicines: clinical supply agreement for tislelizumab - colorectal cancer (CRC), liver (HCC), and small cell lung cancer (SCLC) ° Roche: master agree
Slide 5: Robust Pipeline
ROBUST PIPELINE Ateganosine (THIO) Telomere Targeting Agent ical Tri Indication Treatment Status _ Preclinical Phase 1 Phase 2 Phase 3 THIO-104 NSCLC Libtayo® Phase 3 Ateganosine> Ongoing ITTORTAI Nscic A'téancsine> Cngcing ee co Ateganosine> Planned tislelizumab Phase 2 i Clinical supply SCLC Atega
Slide 6: Ateganosine (THIO)
EGANOSINE (THIO) Ateganosine (THIO, 6-thio-2'-deoxyguanosine) has a novel dual mechanism of action In cancer cells o Telomere-Targeting Ateganosine is guanine-analog small molecule that is incorporated into telomeres by the enzyme telomerase (present in over 80% of human cancers) ° Telomeric structu
Slide 7: Preclinical NSCLC response with ateganosine followed by CPI
Cycle 1 Cycle 2 —e—Control 1000 —e—Atezolizumab 900 —e—Ateganosine 800 —e—Ateganosine > Atezo — 700 No cancer = . = immune memory = 600 due to Ateganosine = 500 Rechallenge with 2 100 5x more lung cancer cells with S$ no additional treatment 5 300 E 200 No recurrence e 100 20% PR 60% CR ) 0 10 20 30
Slide 8: Vast Applicability
VAST APPLICABILITY Sequential combination with any checkpoint inhibitor (CPI) Examples of commercially available CPls Vustayo’ TEVIMBRA (cemiplimab) (tislelizumab) REGENERON | 'iBeOne “recentRIg’ | KEYTRUDA (atezolizumab) | (Pembrolizumab) Genentech | ¢€) MERCK SIMFINZr Jemperli 2% : (durvalumab) —
Slide 9: NSCLC Clinical Trials
NSCLC CLINICAL TRIALS
Slide 10: THIO-101 Phase 2 Trial (Ongoing)
THIO-101 PHASE 2 TRIAL (ONGOING) A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Efficacy/Safety/Dose Selection Modified 3+3
Slide 11: THIO-104 Phase 3 Pivotal Trial (Ongoing)
THIO-104 PHASE 3 PIVOTAL TRIAL (ONGOING) NYSE American: MAIA A Multicenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors and Chemotherapy NSerGse | HE —
Slide 12: Market Entry Strategy
MARKET ENTRY STRATEGY 3L NSCLC is an excellent market entry segment: ¢ Highly unmet medical need in this immunotherapy- resistant and chemotherapy-resistant population ¢ Nocurrent standard of care for this setting ¢ Large population ¢ Limited competition for clinical trials patients ¢ Best results o
Slide 13: Expected Efficacy in Trials in NSCLC 3L
EXPECTED EFFICACY IN TRIALS IN NSCLC 3L THIO-101 Phase 2 Ateganosine + Libtayo® (n = 137-148) ¢ CPI+ Platinum Resistant TargotPopulatien ¢ Prior treatment with docetaxel ORR >30%' THIO-104 Pivotal Phase 3 Ateganosine + Libtayo® Chemotherapy (n = 150) (n= 150) ¢ CPI+ Platinum Resistant ¢ Stratified:
Slide 14: Probability of Technical Success
PROBABILITY OF TECHNICAL SUCCESS NYSE American: MAIA THIO-104 Design Bayesian Assurance? Calculation * OS is the primary endpoint * 90% power to detect HR=0.62, median All 3L patients from THIO-101 9.4 months vs 5.8 months! (chemo) Control: * Interim analysis boundary 1-sided * Median OS assumption
Slide 15: Planned Trials in Other Tumor Types
PLANNED TRIALS IN OTHER TUMOR TYPES
Slide 16: Phase 2 Trials in CRC, SCLC and HCC with Tislelizumab
NYSE American: MAIA Multicenter, Open-label, Phase 2 Trials Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Tislelizumab in CRC, SCLC and HCC Part A/B: Part C: Pivotal Safety/Efficacy Signal (n=~40) Phase 2 (n=~80) THIO-102-CRC ; immune _ Colorectal Cancer Ateg
Slide 17: Colorectal Rationale
COLORECTAL RATIONALE Preclinical Studies in Colorectal Cancer (CRC) e Ateganosine (THIO) followed by CPI results in 100% complete response ° Only 2 cycles of therapy were administered on weeks 1 and 2; no further therapy throughout the study ° No recurrence after long-term follow-up e Anticancer imm
Slide 18: SCLC & HCC - Awarded Orphan Drug Designation
SCLC & HCC - AWARDED ORPHAN DRUG DESIGNATIO NYSE American: Preclinical Studies in Small Cell Lung Cancer (SCLC) Preclinical Studies in Hepatocellular Carcinoma (HCC) ° Ateganosine (THIO) is synergistic with anti-PD-1 agent e Ateganosine is highly synergistic and effective in Pembrolizumab in Small C
Slide 19: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS Ateganosine (THIO) achieved complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models Tumor Volume (mm°) 6007 -© Control -@ Ateganosine 400- 200+ 100% CR 4 0« 0 5 101520 2530354045 Days A
Slide 20: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY ¢ When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated ¢ Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented ¢ Administration of ateganosine (THIO) a
Slide 21: Investment Opportunity
INVESTMENT OPPORTUNITY
Slide 22: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Vlad Vitoc, MD, MBA Founder and CEO 25+ years in Oncology Pharma/ Biotech: Commercial, Medical 12 compounds launched across 20+ tumor types Leadership roles at Bayer (Nexavar), Astellas (Tarceva, Xtandi), Cephalon (Treanda), Novartis (Zometa), Incyte Jakafi) Sergei Gryazn
Slide 23: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY Goal: New Chemical Entity (NCE) Marketing Exclusivity ¢ Ateganosine (THIO) has never been previously approved by the FDA for commercialization ¢ Robust exclusivity o US: Upon FDA approval - 5 years NCE (with additional 2 years based on Hatch Waxman for potential
Slide 24: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY NYSE American: MAIA © Developing agents for the top ; tumor types markets globally NSCLC (#1 WW) * Mortality: 1.7M * Sales: $34B * Mortality: 0.8M * Sales: $3.8B Hepatocellular Carcinoma Colorectal Cancer (#2 WW) ¢ Mortality: 1.0M * Sales: $20B ¢ Mortality: 0.3M ° Sale
Slide 25: Thank You
THANK YOU MAIA BIOTECHNOLOGY NYSE American: MAIA Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606
MAIA Biotechnology — Investor Presentation (January 2026) on 6ix